Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre
Shi, YK; Hu, XS; Zhang, SC; Lv, DQ; Wu, L; Yu, QT; Zhang, YP; Liu, L; Wang, X; Cheng, Y; Ma, ZY; Niu, HR; Wang, D; Feng, JF; Huang, C; Liu, CL; Zhao, H; Li, JZ; Zhang, XD; Jiang, Y; Gu, C
Shi, YK (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Beijing Key Lab Clin Study Anticancer Mol Targete, Beijing 100021, Peoples R China.; Shi, YK (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Beijing 100021, Peoples R China.; Shi, YK (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Beijing 100021, Peoples R China.
LANCET RESPIRATORY MEDICINE, 2021; 9 (8): 829
